Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VNDA vs VOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VOR Captures Overall Composite Edge (57.8 HOLD vs 49.0 HOLD), While VNDA Leads 3–2 on Growth & Valuation Pillars

VOR Overall Winner 6-Pillar Tally: VNDA 3 – 2 VOR (1 Tie) Matrix Metrics: VNDA 3 – 7 VOR

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Vanda Pharmaceuticals Inc. (VNDA) on higher Unified Composite conviction (57.8/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 7–3 (led by Profitability & Quality, Options & Positioning), while VNDA wins 3–2 across the 6-pillar growth and valuation breakdown. VNDA trades at $3.79 (103.1x Forward P/E, -77.6% operating margin) versus VOR at $19.26 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. VNDA 49.0/100 HOLD) and 1.91β · 61% Vol risk profile, whereas VNDA leads top-line expansion (+24.1% YoY revenue growth, 2.23x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VNDA vs VOR
VNDA NASDAQ
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46
VOR NASDAQ Head-to-Head Winner
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$19.26
-0.82% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.91β · 61% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $19.48 · SMA50: $19.87

6-Pillar Scorecard Institutional Category Breakdown (VNDA 3 – 2 VOR)

Columns: Metric · VNDA · VOR
1. Valuation Multiples VNDA
Forward P/E 103.1x N/M
Trailing P/E 103.1x 0.1x
PEG Ratio 2.23x N/M
EV / Revenue 0.9x N/M
2. Growth & Scale VNDA
Revenue Growth (YoY) +24.1% +0.0%
Earnings Growth (YoY) -95.9% +0.0%
TTM Revenue (USD) $229M N/A
Market Cap $238.9M $1.2B
3. Profitability & Quality VOR
Gross Margin 93.6% N/A
Operating Margin -77.6% 0.0%
Net Profit Margin -119.9% 0.0%
Return on Equity (ROE) -82.5% -125.4%
4. Balance Sheet & Cash Flow VNDA
Cash Generation (TTM) -$150M -$1.63B
Cash Flow Margin -65.4% N/A
Net Cash / Leverage $40M Net Cash $1.04B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VOR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 163.3% (75th %ile) 127.0% (6th %ile)
Put/Call OI Skew N/A 2.03x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VNDA (3) vs VOR (7)
Institutional Metric VNDA VOR Criterion Row Edge
Market Capitalization
Scale
$238.9M $1.2B Larger Scale VOR
Trailing P/E Ratio
Valuation
103.1x 0.1x Lower Multiple VOR
Forward P/E Ratio
Valuation
103.1x N/M Lower Multiple VNDA
Revenue Growth (YoY)
Growth
+24.1% +0.0% Higher Growth VNDA
Operating Margin (TTM)
Profitability
-77.6% 0.0% Higher Margin VOR
Net Profit Margin
Profitability
-119.9% 0.0% Higher Margin VOR
Return on Equity (ROE)
Capital Efficiency
-82.5% -125.4% Higher ROE VNDA
52-Week Range Position
Momentum
4% ($4–$10) 65% ($6–$26) Stronger Trend VOR
Beta / 30D Volatility
Risk Regime
1.25β · 61% Vol 1.91β · 61% Vol Lower Realized Risk VOR
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 57.8 / 100 (HOLD) Higher Composite VOR
Trailing 12M Revenue (USD)
Operating Scale
$229M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.23x PEG · 0.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($40M Net Cash) -$1.63B ($1.04B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VOR +12.65 pp
VNDA: -5.83% · VOR: +6.82%
3M Horizon VOR +12.97 pp
VNDA: -30.24% · VOR: -17.27%
6M Horizon VOR +73.89 pp
VNDA: -37.58% · VOR: +36.31%
1Y Horizon VOR +110.1 pp
VNDA: -12.56% · VOR: +97.54%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VNDA vs VOR. Trailing 12-month operating profitability (VNDA -77.6% vs VOR 0.0%) and valuation multiples (VNDA 103.1x vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VNDA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$229M
Gross Margin93.6%
Op. Margin-77.6%
ROE / Fwd P/E-82.5% · 103.1x
VOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-125.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VOR CONSOLIDATION
52d in phase · OBV NEUTRAL
Current IV 127.0%
IV Percentile 6th %ile
Put/Call OI Skew 2.03x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VOR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VNDA vs VOR Key Questions & Quantitative Answers

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Vanda Pharmaceuticals Inc. (VNDA) on higher Unified Composite conviction (57.8/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 7–3 (led by Profitability & Quality, Options & Positioning), while VNDA wins 3–2 across the 6-pillar growth and valuation breakdown. VNDA trades at $3.79 (103.1x Forward P/E, -77.6% operating margin) versus VOR at $19.26 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. VNDA 49.0/100 HOLD) and 1.91β · 61% Vol risk profile, whereas VNDA leads top-line expansion (+24.1% YoY revenue growth, 2.23x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VNDA leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with VOR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VNDA generates $229M in USD-normalized revenue versus N/A for VOR. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VOR.

VNDA screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus VOR (-125.4% ROE) capital efficiency.

In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.